Researchers at the National Institutes of Health and their colleagues at Massachusetts General Hospital (MGH) in Boston report that the injectable hormone tesamorelin reduces liver fat and prevents liver fibrosis (scarring) ...
Oct 11, 2019
0
117
Sixteen years ago, a research group at Mayo Medical School published results showing that a protein called TRAIL can kill cells that cause liver fibrosis but no one seemed to follow up on these findings. Now, researchers ...
Sep 13, 2019
0
1610
Researchers have found that a gene known as AEBP1 may play a central role in the development, severity and potential treatment of liver disease, according to a study by Temple University, the Geisinger Obesity Institute and ...
Jul 18, 2019
0
3
Type 2 diabetes mellitus (T2DM) is a risk factor for progression of liver fibrosis in patients with nonalcoholic fatty liver disease (NAFLD), according to a study published online May 21 in the Journal of Gastroenterology ...
May 27, 2019
0
2
The most deadly forms of alcohol-related liver disease appear to be on the rise in the U.S., a new study finds.
May 08, 2019
0
1
Congenital hepatic fibrosis (CHF) is a rare genetic disease that causes malformation and fibrosis (scarring) of the liver. Occurring in roughly one out of every 20,000 births, CHF can lead to an enlarged liver, impaired blood ...
May 08, 2019
0
5
With an estimated 25% of people worldwide affected by nonalcoholic fatty liver disease (NAFLD), there is a large unmet need for accurate, noninvasive measures to enhance early diagnosis and screening of hepatic fibrosis. ...
Apr 16, 2019
0
1
(HealthDay)—A considerable proportion of young adults have fibrosis and steatosis of the liver, according to a study presented at The International Liver Congress 2019, held from April 10 to 19 in Vienna.
Apr 12, 2019
0
1
AKR1B10 is a useful serum biomarker for advanced liver fibrosis in Nonalcoholic steatohepatitis, and combined with serum WFA(+)-M2BP, it can predict hepatocellular carcinoma development, gastroesophageal varix formation, ...
Apr 12, 2019
0
0
A prespecified interim analysis of the ongoing Phase 3 REGENERATE study has confirmed that obeticholic acid (OCA) is effective in the treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis. The 18-month analysis, ...
Apr 11, 2019
0
1
